The bloc is trying to learn the lessons after largely missing out on the internet revolution and failing to produce any major competitors to match the giants of Silicon Valley or their Chinese counterparts.
Mamer said von der Leyen decided not to make "an issue out of it" and in the conversation brought up women's rights and the Istanbul Convention on violence against women, from which Turkey withdrew last month.
"If this situation does not change, we will have to reflect on how to make exports to vaccine-producing countries dependent on their level of openness," EU Commission President Ursula von der Leyen told a news conference.
"We are ready to use whatever tools we need to deliver on that," von der Leyen said.
The EU has so far approved three vaccines -- Pfizer-BioNTech, Moderna and AstraZeneca-Oxford. Three other vaccines are under "rolling review" by the Amsterdam-based EMA -- Novavax, CureVac and Russia's Sputnik.